# Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer

> **NCT05730673** · PHASE2 · WITHDRAWN · sponsor: **CytoDyn, Inc.**

## Conditions studied

- CCR5
- Microsatellite Stable
- Metastatic
- Colorectal Cancer

## Interventions

- **DRUG:** 700mg leronlimab weekly dose
- **DRUG:** 80mg Regorafenib at week 1
- **DRUG:** 120mg Regorafenib at week2
- **DRUG:** 160 mg Regorafenib at week 3

## Key facts

- **NCT ID:** NCT05730673
- **Lead sponsor:** CytoDyn, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-09-20
- **Primary completion:** 2023-05-27
- **Final completion:** 2023-08-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No participants enrolled
- **Last updated:** 2023-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05730673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05730673, "Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05730673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*